ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 150

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Jennifer Frankovich1, Kirstin Anderson 2, Gonzalo Montero-Martin 3, Avis Chan 4, Margo Thienemann 5, Bahare Farhadian 6, Theresa Willett 5, Elizabeth Mellins 7, Alicia Madden 5, Tanya Murphy 8, Susan Swedo 9, Marcelo Fernandez-Vina 3 and Jill Hollenbach 2, 1Stanford, 2University of California San Francisco, San Francisco, California, 3Stanford University, Palo Alto, California, 4Stanford University School of Medicine, Palo Alto, 5Stanford University School of Medicine, Palo Alto, California, 6Stanford Immune Behavioral Health Clinic and PANS Research Program at Lucile Packard Children's Hospital, Palo Alto, 7Stanford University, Stanford, 8University of South Florida, Tampa, Florida, 9National Institute of Mental Health, Bethesda, Maryland

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: human leukocyte antigens (HLA), KIR (Killer Ig like receptor), OCD, PANS

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is characterized by abrupt onset of obsessive-compulsive disorder (OCD) and/or food restriction with other specified neuropsychiatric symptoms. Patients with PANS have been observed to have co-existing arthritis, immunodeficiency and autoimmune diseases, and/or first degree family members with autoimmune diseases. Our previous study of human leukocyte antigen (HLA) variation in PANS showed significant HLA-B associations including HLA-B38, HLA-B52 and HLA-B27, predominantly B27:02 (Frankovich et al. CARRA Conference 2019). Amino acid level analysis revealed that HLA-B associations could be attributed to variation at positions 80-83 of the molecule, which define the Bw4 serological epitope. Because HLA-Bw4 is the ligand for the inhibitory receptor KIR3DL1 on the surface of natural killer cells (Figure 1), we extended our work to investigate polymorphism of KIR3DL1 in the context of its HLA class I ligands in a cohort of PANS patients and controls.

Methods: Our study sample included 134 unrelated European-ancestry probands from three centers, who met PANS diagnostic criteria (Swedo et al., Pediatr Therapeut 2012), and 1,748 previously sequenced European-ancestry controls (Hollenbach et al., PNAS 2019). We performed next-generation sequencing (NGS) using a novel method and custom bioinformatics (Norman, Hollenbach, et al., AJHG 2016) to  determine allelic polymorphism of KIR3DL1 from genomic DNA in patients with PANS and healthy controls, and analyzed the data with respect to its ligand encoded by HLA-A, HLA-B, and HLA-C.

Results: We found that KIR3DL1*002 with HLA-Bw4 was strongly associated with PANS when compared to controls (OR=1.84, 95% CI, 1.18-2.78, p=0.005) (Figure 2). KIR3DL1*002 encodes a KIR inhibitory allotype that is expressed at high levels on the surface of NK cells.

Conclusion: This immunogenetic finding complements our clinical observations in which patients with PANS have a high rate of arthritis (38.8%), other autoimmune diseases like psoriasis, celiac disease, and thyroiditis (17.3%), blood dyscrasias (e.g., leukopenia, lymphopenia) and elevated levels of auto-antibodies (10-20%).(Chan et al. CARRA conference 2019) Concurrent primary immunodeficiency is also common in patients with PANS, with a prevalence rate of 4% (manuscript submitted), and all of these patients had defects in humoral immunity. Siblings and parents of patients with PANS also reported more immune-mediated diseases than healthy controls (adjusted OR 2.80, 95% CI, 1.64-4.76, p< 0.001). This study shows that a specific, high-expression KIR allele, KIR3DL1*002, in combination HLA-Bw4 confers an increased risk in PANS. Together with other immunologic and epidemiologic findings, these immunogenetic findings argue strongly for immune dysregulation as a key contributor to PANS pathophysiology.

Figure 1. Interaction between KIR and a different part of the HLA molecule from TCR. [Picture extracted from Parham P et al. Philos Trans R Soc Lond B Biol Sci 2012;367(1590):800_811]

Figure 2. Associations with KIR loci in a cohort of patients with PANS when compared to controls.


Disclosure: J. Frankovich, None; K. Anderson, None; G. Montero-Martin, None; A. Chan, None; M. Thienemann, None; B. Farhadian, None; T. Willett, None; E. Mellins, None; A. Madden, None; T. Murphy, None; S. Swedo, None; M. Fernandez-Vina, None; J. Hollenbach, None.

To cite this abstract in AMA style:

Frankovich J, Anderson K, Montero-Martin G, Chan A, Thienemann M, Farhadian B, Willett T, Mellins E, Madden A, Murphy T, Swedo S, Fernandez-Vina M, Hollenbach J. The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/the-killer-immunoglobulin-like-receptor-kir3dl1-in-combination-with-hla-bw4-is-associated-with-pediatric-acute-onset-neuropsychiatric-syndrome-pans/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-killer-immunoglobulin-like-receptor-kir3dl1-in-combination-with-hla-bw4-is-associated-with-pediatric-acute-onset-neuropsychiatric-syndrome-pans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology